1
|
Hoogendoorn S, van Puijvelde GHM, van der Marel GA, van Koppen CJ, Timmers CM, Overkleeft HS. Fluorescent small-molecule agonists as follicle-stimulating hormone receptor imaging tools. RSC Chem Biol 2020; 1:263-272. [PMID: 34458765 PMCID: PMC8341919 DOI: 10.1039/d0cb00068j] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Accepted: 07/20/2020] [Indexed: 01/25/2023] Open
Abstract
Fluorescent cell surface receptor agonists allow visualization of processes that are set in motion by receptor activation. This study describes the synthesis of two fluorescent, low molecular weight ligands for the follicle-stimulating hormone receptor (FSHR), based on a dihydropyridine (DHP) agonist. We show that both BODIPY- and Cy5-conjugated DHP (m-DHP-BDP and m-DHP-Cy5) are potent FSHR agonists, able to activate receptor signalling with nanomolar potencies and to effect receptor internalisation at higher concentrations. FSHR-dependent uptake of m-DHP-Cy5 is in stark contrast to the cellular uptake of m-DHP-BDP which was efficiently internalised also in the absence of FSHR. Our results comprise a first-in-class fluorescent low molecular weight ligand for in situ FSHR imaging and pertain the potential means for targeted delivery of drugs into the endolysosomal pathway of FSHR-expressing cells. Discovery of a potent, small-molecule, fluorescent agonist of the follicle-stimulating hormone receptor (FSHR) for selective staining of FSHR-expressing cells.![]()
Collapse
Affiliation(s)
- Sascha Hoogendoorn
- Leiden Institute of Chemistry, Leiden University Einsteinweg 55 2300 RA Leiden The Netherlands
| | - Gijs H M van Puijvelde
- Leiden Academic Centre for Drug Research, Leiden University Einsteinweg 55 2300 RA Leiden The Netherlands
| | - Gijs A van der Marel
- Leiden Institute of Chemistry, Leiden University Einsteinweg 55 2300 RA Leiden The Netherlands
| | | | | | - Herman S Overkleeft
- Leiden Institute of Chemistry, Leiden University Einsteinweg 55 2300 RA Leiden The Netherlands
| |
Collapse
|
2
|
Paradigms in Fluorescence Molecular Imaging: Maximizing Measurement of Biological Changes in Disease, Therapeutic Efficacy, and Toxicology/Safety. Mol Imaging Biol 2020; 21:599-611. [PMID: 30218390 DOI: 10.1007/s11307-018-1273-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Fluorescence molecular imaging (MI) is an important concept in preclinical research that focuses on the visualization of cellular and biological function in a non-invasive fashion to better understand in vivo disease processes and treatment effects. MI differs fundamentally from traditional preclinical imaging strategies in that it generally relies on reporter probes specific for particular targets or pathways that can be used to reveal biological changes in situ, at the site(s) of disease. In contrast, the more established imaging modalities, like magnetic resonance imaging, X-ray, micro X-ray computed tomography, and ultrasound, historically have relied primarily on late-stage anatomical or physiologic changes. The practical application of fluorescence MI, however, has drifted somewhat from the emphasis on quantifying biology, and based on the publication record, it now appears to include any imaging in which a probe or contrast agent is used to non-invasively acquire in vivo endpoint information. Unfortunately, the mere use of a defined biologically specific probe, in the absence of careful study design, does not guarantee that any useful biological information is actually gained, although often useful endpoint results still can be achieved. This review proposes to add subcategories of MI, termed MI biological assessment (or MIBA), that emphasize a focus on obtaining early and clear biological changes associated with disease development, therapeutic efficacy, and drug-induced tissue changes. Proper selection of probes and careful study design are critical for maximizing the non-invasive assessment of in vivo biological changes, and applications of these critical elements are described.
Collapse
|
3
|
Hong SS, Zhang MX, Zhang M, Yu Y, Chen J, Zhang XY, Xu CJ. Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer. Drug Deliv 2018; 25:576-584. [PMID: 29461120 PMCID: PMC6058603 DOI: 10.1080/10717544.2018.1440667] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
The distinct hormone molecules and receptors, such as follicle-stimulating hormone receptor (FSHR) in ovarian cancer, provide opportunities for more precisely targeted therapy. We previously developed FSHR-mediated nanoparticles and found that FSH peptides on the surface of nanoparticles improved the delivery of short interfering RNA (siRNA) into ovarian cancer cells. However, the high toxicity of the nanoparticles and the transient silencing of the siRNA in vivo limited further study. Here, we developed FSH peptide-conjugated nanoparticles with an increased amount of polyethylene glycol (PEG) grafting and encapsulated short hairpin RNA (shRNA) to silence the target gene, growth-regulated oncogene α (gro-α). The nanoparticle complexes exhibited good stability over three weeks. Expression of the target gene, gro-α, was significantly down-regulated by gro-α shRNA-loaded nanoparticles conjugated with FSH peptides (FSH33-G-NP) in FSHR-positive HEY cells. Cell proliferation, migration, and invasion were also inhibited by FSH33-G-NP. Tumor growth was delayed significantly in the mice treated with FSH33-G-NP. No significant loss of body weight or severe toxic effects were observed in any groups. In conclusion, gro-α shRNA-loaded nanoparticles conjugated with FSH peptides overcame the drawbacks of the in vivo application of RNAi therapeutics and polymer-based nanocarriers and showed safe antitumor efficacy. Our study might contribute to the application of FSHR-based targeted therapy and imaging in cancer.
Collapse
Affiliation(s)
- Shan-Shan Hong
- a Obstetrics and Gynecology Hospital , Fudan University , Shanghai , China
| | - Ming-Xing Zhang
- a Obstetrics and Gynecology Hospital , Fudan University , Shanghai , China
| | - Meng Zhang
- a Obstetrics and Gynecology Hospital , Fudan University , Shanghai , China
| | - Yi Yu
- a Obstetrics and Gynecology Hospital , Fudan University , Shanghai , China
| | - Jun Chen
- b Departments of Pharmaceutics, School of Pharmacy , Fudan University , Shanghai , China
| | - Xiao-Yan Zhang
- a Obstetrics and Gynecology Hospital , Fudan University , Shanghai , China.,c Department of Obstetrics and Gynecology of Shanghai Medical School , Fudan University , Shanghai , China.,d Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases , Shanghai , China
| | - Cong-Jian Xu
- a Obstetrics and Gynecology Hospital , Fudan University , Shanghai , China.,c Department of Obstetrics and Gynecology of Shanghai Medical School , Fudan University , Shanghai , China.,d Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases , Shanghai , China
| |
Collapse
|
5
|
PET Imaging of FSHR Expression in Tumors with 68Ga-Labeled FSH1 Peptide. CONTRAST MEDIA & MOLECULAR IMAGING 2017; 2017:2674502. [PMID: 29097913 PMCID: PMC5612759 DOI: 10.1155/2017/2674502] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/29/2017] [Revised: 07/07/2017] [Accepted: 07/25/2017] [Indexed: 12/13/2022]
Abstract
FSHR is an appealing target for cancer theranostics. Radiolabeled FSH1 and its derivatives have shown potential to in vivo detect FSHR expression. However, moderate labeling yields (~50% nondecay-corrected) may partially limit their wide use. 68Ga is an excellent PET nuclide due to availability, nearly quantitative reaction, and short physical half-life. In this study, 68Ga labeled FSH1 peptide was developed for imaging of FSHR in cancers. In vitro studies and MicroPET imaging were performed in PC-3 prostate tumor model. [68Ga] Ga-NOTA-MAL-FSH1 can be produced within 20 min with 93.2 ± 2.1% yield and the radiochemical purity was greater than 95%. It showed that [68Ga] Ga-NOTA-MAL-FSH1 possessed FSHR binding affinities. The tracer was stable in PBS and human serum for at least 2 hours. MicroPET imaging revealed that the PC-3 xenografts were clearly visualized and the tumor uptakes were 1.87 ± 0.10, 1.26 ± 0.06, and 0.71 ± 0.10% ID/g at 0.5, 1 h, and 2 h postinjection. The corresponding tumor to blood and tumor to muscle ratios were 1.77 ± 0.70, 7.94 ± 1.35, and 10.37 ± 1.16 and 7.42 ± 0.46, 26.13 ± 2.99, and 36.40 ± 2.54, respectively. FSHR binding specificity was also demonstrated by reduced tumor uptake of [68Ga] Ga-NOTA-MAL-FSH1 after coinjecting excess unlabeled FSH1 peptide. The favorable characters of [68Ga] Ga-NOTA-MAL-FSH1 such as convenient synthesis and specific tumor uptake warrant its further investigation for FSHR expression imaging.
Collapse
|
6
|
Feng Y, Zhu S, Antaris AL, Chen H, Xiao Y, Lu X, Jiang L, Diao S, Yu K, Wang Y, Herraiz S, Yue J, Hong X, Hong G, Cheng Z, Dai H, Hsueh AJ. Live imaging of follicle stimulating hormone receptors in gonads and bones using near infrared II fluorophore. Chem Sci 2017; 8:3703-3711. [PMID: 28626555 PMCID: PMC5465568 DOI: 10.1039/c6sc04897h] [Citation(s) in RCA: 72] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2016] [Accepted: 03/05/2017] [Indexed: 12/14/2022] Open
Abstract
In vivo imaging of hormone receptors provides the opportunity to visualize target tissues under hormonal control in live animals. Detecting longer-wavelength photons in the second near-infrared window (NIR-II, 1000-1700 nm) region affords reduced photon scattering in tissues accompanied by lower autofluorescence, leading to higher spatial resolution at up to centimeter tissue penetration depths. Here, we report the conjugation of a small molecular NIR-II fluorophore CH1055 to a follicle stimulating hormone (FSH-CH) for imaging ovaries and testes in live mice. After exposure to FSH-CH, specific NIR-II signals were found in cultured ovarian granulosa cells containing FSH receptors. Injection of FSH-CH allowed live imaging of ovarian follicles and testicular seminiferous tubules in female and male adult mice, respectively. Using prepubertal mice, NIR-II signals were detected in ovaries containing only preantral follicles. Resolving earlier controversies regarding the expression of FSH receptors in cultured osteoclasts, we detected for the first time specific FSH receptor signals in bones in vivo. The present imaging of FSH receptors in live animals using a ligand-conjugated NIR-II fluorophore with low cell toxicity and rapid clearance allows the development of non-invasive molecular imaging of diverse hormonal target cells in vivo.
Collapse
Affiliation(s)
- Yi Feng
- Program of Reproductive and Stem Cell Biology , Department of Obstetrics and Gynecology , Stanford University School of Medicine , Stanford , CA 94305 , USA .
| | - Shoujun Zhu
- Department of Chemistry , Stanford University , Stanford , CA 94305 , USA .
| | | | - Hao Chen
- Key Laboratory of Virology , Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals , Wuhan University School of Pharmaceutical Sciences , Wuhan 430071 , China
- Molecular Imaging Program at Stanford (MIPS) , Bio-X Program , Department of Radiology , Stanford University , Stanford , CA 94305 , USA .
| | - Yuling Xiao
- Key Laboratory of Virology , Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals , Wuhan University School of Pharmaceutical Sciences , Wuhan 430071 , China
| | - Xiaowei Lu
- Program of Reproductive and Stem Cell Biology , Department of Obstetrics and Gynecology , Stanford University School of Medicine , Stanford , CA 94305 , USA .
| | - Linlin Jiang
- Program of Reproductive and Stem Cell Biology , Department of Obstetrics and Gynecology , Stanford University School of Medicine , Stanford , CA 94305 , USA .
| | - Shuo Diao
- Department of Chemistry , Stanford University , Stanford , CA 94305 , USA .
| | - Kuai Yu
- Department of Chemistry , Stanford University , Stanford , CA 94305 , USA .
| | - Yan Wang
- Program of Reproductive and Stem Cell Biology , Department of Obstetrics and Gynecology , Stanford University School of Medicine , Stanford , CA 94305 , USA .
| | - Sonia Herraiz
- Program of Reproductive and Stem Cell Biology , Department of Obstetrics and Gynecology , Stanford University School of Medicine , Stanford , CA 94305 , USA .
| | - Jingying Yue
- Department of Chemistry , Stanford University , Stanford , CA 94305 , USA .
| | - Xuechuan Hong
- Key Laboratory of Virology , Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals , Wuhan University School of Pharmaceutical Sciences , Wuhan 430071 , China
| | - Guosong Hong
- Department of Chemistry , Stanford University , Stanford , CA 94305 , USA .
| | - Zhen Cheng
- Molecular Imaging Program at Stanford (MIPS) , Bio-X Program , Department of Radiology , Stanford University , Stanford , CA 94305 , USA .
| | - Hongjie Dai
- Department of Chemistry , Stanford University , Stanford , CA 94305 , USA .
| | - Aaron J Hsueh
- Program of Reproductive and Stem Cell Biology , Department of Obstetrics and Gynecology , Stanford University School of Medicine , Stanford , CA 94305 , USA .
| |
Collapse
|